An open-label Phase II study of combination of TSR-042, bevacizumab, and niraparib in patients with platinum-resistant ovarian cancer (OC): Cohort A of the OPAL trial

被引：0
|
作者：
Liu, Joyce [1 ]
Gunderson, Camille [2 ]
Hendrickson, Andrea Wahner [3 ]
Ratner, Elena [4 ]
Diver, Elisabeth [5 ]
Moroney, John [6 ]
Arend, Rebecca C. [7 ]
Louie-Gao, Melinda [8 ]
Wang, Sarah [8 ]
Luptakova, Katarina [8 ]
Konecny, Gottfried E. [9 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA
[3] Mayo Clin, Dept Oncol, Rochester, MN USA
[4] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA
[5] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Stanford, CA 94305 USA
[6] Univ Chicago Med, Dept Obstet & Gynecol, Chicago, IL USA
[7] Univ Alabama Birmingham, Obstet & Gynecol, Birmingham, AL USA
[8] TESARO Inc, Waltham, MA USA
[9] Univ Calif Los Angeles, Med Ctr, Dept Med, Santa Monica, CA USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-CT157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT157
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase I/II study of maplirpacept in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer (OC): Phase 1 results
    Street, Daron G.
    Kuttschreuter, Luke
    Starks, David
    Mahdi, Haider
    Linn, Carlos
    Pavlov, Dmitri
    Peguero, Julio Antonio
    Chawla, Sant P.
    Bruns, Ingmar
    Waggoner, Steven E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] A phase II trial of voreloxin in women with platinum-resistant ovarian cancer
    Hirte, H. W.
    McGuire, W.
    Edwards, R.
    Husain, A.
    Hoskins, P.
    Michels, J.
    Matulonis, U.
    Sexton, C.
    Michelson, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
    Necchi, Andrea
    Mariani, Luigi
    Zaffaroni, Nadia
    Schwartz, Lawrence H.
    Giannatempo, Patrizia
    Crippa, Flavio
    Morosi, Carlo
    Lanocita, Rodolfo
    Sava, Teodoro
    Ortega, Cinzia
    Messina, Caterina
    Sacco, Cosimo
    Pennati, Marzia
    Daidone, Maria G.
    Nicolai, Nicola
    De Braud, Filippo
    Gianni, Alessandro M.
    Salvioni, Roberto
    LANCET ONCOLOGY, 2012, 13 (08): : 810 - 816
  • [24] Combined regimen of inhalable STING agonist plus chemoimmunotherapy in platinum-resistant or platinum-refratory ovarian cancer: A randomized, open-label, phase II trial.
    Zhang, Yan
    Mei, Qian
    Meng, Yuanguang
    Chen, Meixia
    Liu, Yang
    Yang, Qingming
    Han, Weidong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer
    Stockler, Martin R.
    Hilpert, Felix
    Friedlander, Michael
    King, Madeleine T.
    Wenzel, Lari
    Lee, Chee Khoon
    Joly, Florence
    de Gregorio, Nikolaus
    Angel Arranz, Jose
    Mirza, Mansoor Raza
    Sorio, Roberto
    Freudensprung, Ulrich
    Sneller, Vesna
    Hales, Gill
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (13) : 1309 - +
  • [26] Combination therapy with Bevacizumab and GEMOX for patients with platinum-resistant recurrent ovarian cancers: A phase ll study
    Takano, M.
    Ikeda, Y.
    Oda, K.
    Kouta, H.
    Kudoh, K.
    Kita, T.
    Sasaki, N.
    Goto, T.
    Furuya, K.
    Kikuchi, Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S730 - S730
  • [27] Open-label, phase 2 study of adebrelimab combined with fuzuloparib in the treatment of patients with HRD-positive, recurrent platinum-resistant ovarian cancer
    Chen, Jian
    Zou, JianPing
    Yu, Haijuan
    Liu, Li
    Zang, Lele
    Sun, Yang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer
    Liu, Joyce
    Burris, Howard
    Wang, Judy S.
    Barroilhet, Lisa
    Gutierrez, Martin
    Wang, Yulei
    Vaze, Anjali
    Commerford, Renee
    Royer-Joo, Stephanie
    Choeurng, Voleak
    Humke, Eric
    Moore, Kathleen
    GYNECOLOGIC ONCOLOGY, 2021, 163 (03) : 473 - 480
  • [29] Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial
    Coleman, Robert L.
    Handley, Katelyn F.
    Burger, Robert
    Dal Molin, Graziela Zibetti
    Stagg, Robert
    Sood, Anil K.
    Moore, Kathleen N.
    GYNECOLOGIC ONCOLOGY, 2020, 157 (02) : 386 - 391
  • [30] Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer
    Nakka, Thejeswar
    Goenka, Luxitaa
    Dubashi, Biswajit
    Kayal, Smita
    Mathaiyan, Jayanthi
    Barathi, Deepak
    Krishnamoorthy, Narendran
    Thumaty, Divya Bala
    Dahagama, Sindhu
    Ganesan, Prasanth
    MEDICAL ONCOLOGY, 2022, 39 (12)
12345